Will Boehringer Ingelheim’s ‘nintedanib’ become a victim of the risk sharing system?

As Ildong Pharmaceutical’s idiopathic pulmonary fibrosis(IPF) treatment, ‘Pirespa(generic name: pirfenidone)’ has acquired the health insurance application, its follow-up substance, Boehringer Ingelheim’s nintedanib, is in trouble.

According to the revision of the drug insurance benefit list and the benefit ceiling price sheet which was officially announced on the last 2^nd, the health insuranc...